Protalix BioTherapeutics
PLX
34 hedge funds and large institutions have $6.04M invested in Protalix BioTherapeutics in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
1,347% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $235K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
31% more funds holding
Funds holding: 26 → 34 (+8)
24% more capital invested
Capital invested by funds: $4.87M → $6.04M (+$1.17M)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
1.92% less ownership
Funds ownership: 7.04% → 5.12% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.73M |
| 2 |
Two Sigma Investments
New York
|
+$323K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$278K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$264K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$3.31M |
| 2 |
Jane Street
New York
|
-$92.2K |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$19.3K |
| 4 |
SSWM
Smith Salley Wealth Management
Greensboro,
North Carolina
|
-$16.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5.14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $9.85K | +$8.02K | +4,571 | +3,809% |
|
|
TC
27
Truvestments Capital
Sarasota,
Florida
| $8.15K | +$6.81K | +3,880 | New |
|
|
PVH
28
Psagot Value Holdings
Tel Aviv,
Israel
| $7K | -$3.96K | -2,256 | -38% |
|
29
Barclays
London,
United Kingdom
| $4.2K | – | – | – |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $3K | +$2.81K | +1,602 | New |
|
31
Osaic Holdings
Scottsdale,
Arizona
| $1.26K | +$177 | +101 | +20% |
|
|
FDCDDQ
32
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $525 | – | – | – |
|
33
Commonwealth Equity Services
Waltham,
Massachusetts
| $105 | – | – | – |
|
|
34
Bank of America
Charlotte,
North Carolina
| $82 | -$5.14K | -2,928 | -99% |
|
|
HCM
35
Highbridge Capital Management
New York
| – | -$3.31M | -2,413,487 | Closed |
|
|
SSWM
36
Smith Salley Wealth Management
Greensboro,
North Carolina
| – | -$16.5K | -12,048 | Closed |
|
|
TCWA
37
Ten Capital Wealth Advisors
Spokane,
Washington
| – | -$1.37K | -1,000 | Closed |
|
PLX Hedge Fund Activity: Q1 2023 in Review
34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2023, worth a combined $6.04M — up 24% from $4.87M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PLX positions and 3 closed out — a net gain of 8 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.73M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $3.31M sold.
- 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2023, up from 26 in Q4 2022.
- Funds reported $6.04M of Protalix BioTherapeutics stock for Q1 2023, up 24% quarter-over-quarter.
- 11 funds opened new Protalix BioTherapeutics positions in Q1 2023 and 3 closed out, a net change of +8 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $1.73M added.
- The largest Protalix BioTherapeutics seller in Q1 2023 was Highbridge Capital Management, an estimated $3.31M sold.
Based on aggregated 13F filings for Q1 2023.